Quotient, a U.K. focused on blood transfusion diagnostics, unveiled plans for an initial public offering that would raise as much as $75 million. The move continues a steady trickle of IPO movement among testing companies that began late last fall.
Vermillion's latest financial report yielded a mixed bag of results: Although the company reported a widening net loss due to increased spending for its research and product development, revenue grew for its software-based ovarian cancer diagnostic.
Biomet, a maker of medical devices based in Warsaw, IN, has reportedly filed with U.S. regulators for an IPO nominally valued at $100 million.
WuXi PharmaTech boosted its revenue 15.6% last year, and China's largest CRO is expecting to match that growth in the new year, counting on steady demand for manufacturing and a larger share of the U.S. research market.
Covidien chief executive José Almeida sold 50,000 shares in his company last Friday, worth $3.6 million at the time he sold them, the Ireland-based medical device maker has disclosed.
Texas devicemaker Kinetic Concepts is touting the results of a new independent study that shows its wound-healing therapy system reduces operating room visits and hospital stays compared to the competition.
Merck KGaA's multiple sclerosis treatment Rebif is holding its own. Considering that the German drugmaker's flagship product faces some formidable new competitors--including Biogen Idec's brand-new powerhouse, Tecfidera--that's not too shabby.
Navidea Biopharmaceuticals is hopeful the expected European Union approval of its Lymphoseek injectable diagnostic imaging agent later this month and a $30 million loan will help stanch its financial hemorrhaging, which saw losses from operations spike to $38.4 million for the year compared to $28 million for the same period in 2012.
Mindray Medical ($MR), the Chinese medical device giant, has decided to boost the size of an already impressive share repurchase program, capping a year of double digit growth in both revenue and net income.
Oxford Immunotec Global's first financial report as a publicly traded company revealed a sizable boost in revenue and an improvement in net losses. The positive numbers come at a critical moment, as the company prepares to roll out its new test for tuberculosis.